



(11) **EP 1 355 634 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 9/48 (2006.01) **A61K 9/127** (2006.01)
A61K 9/133 (2006.01) **A61K 31/4745** (2006.01)

(48) Corrigendum issued on:
04.03.2009 Bulletin 2009/10

(86) International application number:
PCT/US2001/043325

(45) Date of publication and mention
of the grant of the patent:
05.11.2008 Bulletin 2008/45

(87) International publication number:
WO 2002/058622 (01.08.2002 Gazette 2002/31)

(21) Application number: **01994079.0**

(22) Date of filing: **09.11.2001**

(54) **SN-38 LIPID COMPLEXES AND METHODS OF USE**

SN-38-LIPIDKOMPLEXE UND VERFAHREN ZU IHRER VERWENDUNG

COMPLEXES LIPIDIQUES A BASE DE SN-38 ET PROCEDES D'UTILISATION

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(56) References cited:
WO-A-00/23052 **WO-A-93/18751**
WO-A-95/08986 **WO-A-99/13816**
US-A- 5 552 156 **US-A- 5 834 012**
US-A- 6 056 973 **US-A- 6 096 336**
US-B1- 6 291 676

(30) Priority: **09.11.2000 US 247306 P**

(43) Date of publication of application:
29.10.2003 Bulletin 2003/44

(73) Proprietor: **Neopharm, Inc.**
Lake Bluff IL 60044 (US)

(72) Inventors:
• **AHMAD, Imran**
Wadsworth, IL 60083 (US)
• **ZHANG, Jia-Ai (Allen)**
Vernon Hills, IL 60601 (US)
• **RAHMAN, Aquilur**
Potomac, MD 20854 (US)

(74) Representative: **Wössner, Gottfried et al**
HOEGER, STELLRECHT & PARTNER
Patentanwälte
Uhlandstrasse 14 c
70182 Stuttgart (DE)

- **LUNDBERG B B: "BIOLOGICALLY ACTIVE CAMPTOTHECIN DERIVATIVES FOR INCORPORATION INTO LIPOSOME BILAYERS AND LIPID EMULSIONS" ANTI-CANCER DRUG DESIGN, BASINGSTOKE, GB, vol. 13, no. 5, 1998, pages 453-461, XP000878681 ISSN: 0266-9536**
- **SADZUKA Y: "Effective prodrug liposome and conversion to active metabolite" CURRENT DRUG METABOLISM, BENTHAM SCIENCE PUBLISHERS,, US, vol. 1, no. 1, 2000, pages 31-48, XP002954303 ISSN: 1389-2002**
- **SADZUKA Y ET AL: "EFFECT OF LIPOSOMALIZATION ON THE ANTITUMOR ACTIVITY, SIDE-EFFECTS AND TISSUE DISTRIBUTION OF CPT-11" CANCER LETTERS, NEW YORK, NY, US, vol. 127, no. 1/2, 15 May 1998 (1998-05-15), pages 99-106, XP000878677 ISSN: 0304-3835**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 355 634 B8

- GOKHALE PC ET AL: "AN IMPROVED METHOD OF ENCAPSULATION OF DOXORUBICIN IN LIPOSOMES: PHARMACOLOGICAL, TOXICOLOGICAL AND THERAPEUTIC EVALUATION" BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 74, no. 1, July 1996 (1996-07), pages 43-48, XP000961424 ISSN: 0007-0920
- BURKE T G ET AL: "Lipid bilayer partitioning and stability of camptothecin drugs" BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 32, no. 20, 25 May 1993 (1993-05-25), pages 5352-5364, XP002288627 ISSN: 0006-2960
- EMERSON D L: "Liposomal delivery of camptothecins" PHARMACEUTICAL SCIENCE AND TECHNOLOGY TODAY, ELSEVIER TRENDS JOURNALS, CAMBRIDGE,, GB, vol. 3, no. 6, 1 June 2000 (2000-06-01), pages 205-209, XP002235822 ISSN: 1461-5347